Cumberland Pharmaceuticals Inc.
Compositions and methods of treating muscular dystrophy with thromboxane-A.sub.2 receptor antagonists

Abstract:

The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A.sub.2 receptor antagonist.